Stifel Nicolaus analyst Paul Matteis maintained a Buy rating on Dyne Therapeutics (DYN – Research Report) yesterday and set a price target of ...

H.C. Wainwright lowered the firm’s price target on Dyne Therapeutics (DYN) to $46 from $55 and keeps a Buy rating on the shares. The firm cites ...

So should Dyne Therapeutics (NASDAQ:DYN) shareholders be worried about its cash burn? In this article, we define cash burn as its annual (negative) free cash flow, which is the am ...

Dyne Therapeutics, Inc. (DYN) has been beaten down lately with too much selling pressure. While the stock has lost 10.4% over the past four weeks, there is light at the end of the tunnel as it is now ...

WALTHAM, Mass., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage neuromuscular disease company focused on advancing life-transforming therapeutics for ...

With its recent data drop for an oligonucleotide candidate, Dyne Therapeutics signals it may become a frontrunner in this ...

(RTTNews) - Dyne Therapeutics, Inc. (DYN) revealed Loss for fourth quarter that beat the Street estimates. The company's earnings totaled -$89.54 million, or -$0.88 per share. This compares with ...

Full enrollment of Registrational Expansion Cohort of ACHIEVE Trial of DYNE-101 in DM1 Planned for Mid-2025 to Support Submission for U.S. Accelerated Approval - - Full Enrollment of ...

Full enrollment of Registrational Expansion Cohort of ACHIEVE Trial of DYNE-101 in DM1 Planned for Mid-2025 to Support Submission for U.S. Accelerated Approval - - Full Enrollment of Registrational ...